Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

6(75.0%)

Phase 1

1(12.5%)

Early Phase 1

1(12.5%)

8Total

Phase 2(6)

Phase 1(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06270706Phase 1Recruiting

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Role: lead

NCT04480840Phase 2Completed

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

Role: lead

NCT05621252Phase 2Completed

Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)

Role: lead

NCT06097260Phase 2Terminated

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Role: lead

NCT03183570Early Phase 1Completed

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

Role: collaborator

NCT04396756Phase 2Completed

Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis

Role: lead

NCT04072315Phase 2Completed

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/

Role: lead

NCT04565249Phase 2Terminated

Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19

Role: lead

All 8 trials loaded